UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
- TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET
- Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors pageof the Company's website. The archived presentations will also be available there for a limited time after the event.
About Merus
Merusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' websiteand LinkedIn.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
